Investor Hub

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases.

Latest investor presentation
Latest clinical presentation
Latest quarterly earnings
Annual report
Global ticker
Recent News
Jun 23, 2022

The EUA in Taiwan allows Novavax to begin fulfilling its commitment to the COVAX Facility GAITHERSBURG, Md., June 23, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company...

Learn more

Jun 23, 2022

Upon authorization, Nuvaxovid™ would be the first protein-based option for adolescents aged 12 through 17 in Europe Nuvaxovid™ demonstrated 80% efficacy and was generally well-tolerated in...

Learn more

Jun 23, 2022

Novavax today announced the filing of a Supplement to a New Drug Submission with Health Canada to expand the label of Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent...

Learn more

All press releases

Why invest with us

We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

For much of my four-decade career, I’ve worked with biotech companies trying to solve significant health challenges, including HIV. Novavax is uniquely positioned to help end this pandemic with our protein-based vaccine. I believe in NVX-CoV2373 so much.

I came out of retirement to join the fight.

Lisa Dunkle
Vice President, Global Medical Lead for Coronavirus Vaccine

Get notifications for investor updates

Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.

Go to email subscription 

Investor inquiries

Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at

Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.